BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 09, 2007
 |  BioCentury  |  Finance

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 4/5 cls
ArQule (ARQL) Stanford Group Hanzhong Li New Buy 6% $7.92
Li set an $11 target. He believes ARQL's ARQ 197 to treat cancer has blockbuster potential among kinase inhibitors in development. The company plans to begin a Phase II trial of the small molecule inhibitor of c-Met receptor tyrosine kinase this quarter.
Bioenvision (BIVN) Fortis David Garrett Price target Sell -7% $3.81
Garrett lowered...

Read the full 491 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >